AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$SNDX

Metzger Michael A sold $130K of SNDX

Metzger Michael A (Chief Executive Officer) sold 6,847 shares of Syndax Pharmaceuticals Inc (SNDX) at $18.99 ($0.13M total) on 2026-06-01.

Original reporting
SEC EDGAR · Metzger Michael A
Published Jun 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SNDX
Neutral
medium confidence
Mentioned
$SNDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNDXNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity and may marginally influence sentiment, but it does not introduce new company fundamentals such as guidance, trial results, or regulatory decisions.

02

Market read

Traders may monitor insider selling as a sentiment input, but this specific filing lacks fundamental catalysts and is unlikely to drive a durable repricing alone.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article does not provide intent, option exercises, or broader insider activity context beyond this single Form 4.

Relevance 4/10Novelty 3/10Timing: Filed 2026-06-02, transaction dated 2026-06-01 (after-hours disclosure window).

Background

The article is an SEC Form 4 insider transaction disclosure for Syndax Pharmaceuticals, reported by its CEO.

Company-level read

Ticker impact

$SNDXNeutralMedium confidence
Context

Syndax CEO Michael Metzger sold 6,847 shares at $18.99 on 2026-06-01, disclosing $130,024.53 in proceeds via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no new operational, clinical, or financial guidance. Insider sales can be informational, yet this single sale typically does not reset valuation expectations without accompanying company-specific news.

Market effects

Sector

No sector-wide signal; this is an issuer-specific insider transaction in biotech.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the CEO sale is not explicitly tied to a 10b5-1 plan in the filing, some traders may read it as higher near-term risk, even though the article provides no corroborating fundamentals.

Key entities

  • issuer
    Syndax Pharmaceuticals Inc

    Biopharma company whose CEO reported an open-market sale of shares via SEC Form 4.

  • insider
    Metzger Michael A

    CEO and officer/director who sold 6,847 shares at $18.9900 on 2026-06-01.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SNDX insider trading history →

Related articles

NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min
OCT 13
$CMed

Crude Oil Edges Higher; Citigroup Earnings Top Views

Citigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.

benzinga.com7 min
OCT 13
$SNDXMedAI 8/10

Stifel maintains Syndax stock rating after trial failure

Stifel maintained its Buy rating and $40 price target on Syndax Pharmaceuticals (SNDX) after the company's Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed. Syndax will halt further development of the drug for this indication. Stifel noted the setback but kept its positive outlook on Revuforj revenue growth and Niktimvo's potential. SNDX shares fell about 15% post-announcement, trading near their 52-week low.

investing.com2 min